Buy, Sell or Hold: Bristol Myers Squibb (BMY-N) — Stock Predictions at Stockchase

Home Daily Stock Opinions and Ratings Bristol Myers Squibb (BMY-N)

NYSE:BMY

66.98

0.26 (0.39%) 1d

BUY

They have zero economic sensitivity (good) and has enough drugs in the pipeline to beat future estimates. Always pays an above-average dividend.

biotechnology / pharmaceutical

HOLD

In fine shape, can own it for the next 6-9 months of volatility. The way the market is, owning healthcare is safer than owning other things. Very defensive. He owns JNJ and NVO, but any of these companies will be fine.

biotechnology / pharmaceutical

DON'T BUY

A leaking boat that you need to bail out of. Their flagship drug, an oncology one, goes off patent in 2028. Their other drugs go off-patent in 2025-6. 80% of their 2021 revenues will be off-patent by 2028. Trades at 23x PE. All drug companies have these issues, but would rather buy a drug company that's less reliant on a key drug and trades cheaper.

biotechnology / pharmaceutical

BUY

BMY and AbbVie The line is blurred between biotech and pharma. He likes both spaces and both stocks. Aging demographics means more and more drugs. Both are have solid valuations. They pay income but also offer capital appreciation.

biotechnology / pharmaceutical

BUY

biotechnology / pharmaceutical

BUY

Trades at 9x earnings. Has a great pipeline of drugs. Pays a great dividend.

biotechnology / pharmaceutical

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Dec 23/21, Up 15.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMY has triggered its stop at $72. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 15%, when considering the previous recommendation to cover half the position.

biotechnology / pharmaceutical

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Dec 29/21, Up 21.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMY is progressing well. To remain disciplined, we recommend trailing up the stop (from $68) to $72.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Oct 20/20, Up 30%) Quality company. Concerns have abated. Catalyst coming up with cardio drug in the second half of the year. Not very expensive.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Mar 17/22, Up 8%) In the US there's a violent rotation into the drug space that will continue. He models $116, so huge upside.

biotechnology / pharmaceutical

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Dec 23/21, Up 16.2%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with BMY has achieved its $72.50 objective. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $58) to $68.

biotechnology / pharmaceutical

TOP PICK

Likes the drug space in general. Model price of $112, up from today's price of around $70, a 61% upside. Buys back a lot of stock. Huge value. No pullback despite market volatility in last 3 months. You get paid to wait, and in USD. Yield is 3.07%. (Analysts’ price target is $73.42)

biotechnology / pharmaceutical

COMMENT

They have done well recently but he is looking for companies with longer term potential and expiry dates for drug patents. Should have good pipelines. Prefers diabetic care companies since this disease is on the rise. eg. Eli Lilly or Novo Nordisk. Astra Zeneca has a good pipeline in oncology drugs.

biotechnology / pharmaceutical

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Dec 23/21, Up 10.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMY is progressing well. We now recommend trailing up the stop (from $54) to $58.

biotechnology / pharmaceutical

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly We reiterate BMY, a $139 billion marketcap pharma player, as a TOP PICK. The recent $13 billion acquisition of a company that focuses on blood cancer treatment has gone well, but analysts have held the stock value back as the drug will lose patent protection in 2023. If you believe in the strength of management this will not be a game changer. Recent reported earnings beat market expectations by 4% and its ROE is over 40%. It pays a good dividend that has grown over 40% over the past three years. We would continue to use $54 as a stop-loss, looking to achieve $72.50 -- over 16% upside. Yield 3.19% (Analysts’ price target is $72.50)

biotechnology / pharmaceutical

Showing 1 to 15 of 182 entries

Bristol Myers Squibb(BMY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 9

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 11

Stockchase rating for Bristol Myers Squibb is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bristol Myers Squibb(BMY-N) Frequently Asked Questions

What is Bristol Myers Squibb stock symbol?

Bristol Myers Squibb is a American stock, trading under the symbol BMY-N on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY-N

Is Bristol Myers Squibb a buy or a sell?

In the last year, 11 stock analysts published opinions about BMY-N. 9 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bristol Myers Squibb.

Is Bristol Myers Squibb a good investment or a top pick?

Bristol Myers Squibb was recommended as a Top Pick by on . Read the latest stock experts ratings for Bristol Myers Squibb.

Why is Bristol Myers Squibb stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bristol Myers Squibb worth watching?

11 stock analysts on Stockchase covered Bristol Myers Squibb In the last year. It is a trending stock that is worth watching.

What is Bristol Myers Squibb stock price?

On 2023-03-23, Bristol Myers Squibb (BMY-N) stock closed at a price of $66.98.

Trending stocks today

Bristol Myers Squibb (BMY-N)

NYSE:BMY

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Bristol Myers Squibb(BMY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Bristol Myers Squibb(BMY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Bristol Myers Squibb(BMY-N)

Bristol Myers Squibb(BMY-N) Rating

Bristol Myers Squibb(BMY-N) Frequently Asked Questions

What is Bristol Myers Squibb stock symbol?

Is Bristol Myers Squibb a buy or a sell?

Is Bristol Myers Squibb a good investment or a top pick?

Why is Bristol Myers Squibb stock dropping?

Is Bristol Myers Squibb worth watching?

What is Bristol Myers Squibb stock price?

You may also like:

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Brian Madden

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Michael Sprung

Stockchase Insights